New Director takes up Role at MRC Technology

MRC Technology (MRCT) has appointed a Director of Transfer Technology to head up the team responsible for identifying, protecting and progressing promising life science research to improve human health.

Andrew Farquharson, has previously held senior Intellectual Property (IP) roles in AstraZeneca UK and USA, supporting the company’s R&D, Business Development and Government Affairs activities. He runs a consultancy practice, providing IP services to a range of life science and pharmaceutical clients and is appointed to the EU Commission’s Expert Group advising on the European Biotech Directive’s impact on patent law and research & development activity.

Dr Dave Tapolczay, Chief Executive Officer, MRC Technology said: “Andrew’s extensive experience will support our charity’s work to ensure innovative life science research reaches its full potential and benefit a wider range of people. We look forward to having him on board!”

“MRC Technology has a peerless reputation for the development and exploitation of innovative medical research,” Andrew Farquharson responded. “ I am greatly looking forward to joining the MRCT team and using my experience to meet the challenges in ensuring that future innovations are protected and translated into meaningful new therapeutic products made available to patients.”